Arginase

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Vaccine, Society, IO, Society for Immunotherapy of Cancer, SITC, Immunotherapy, PDT, Cell, Arginase, Location, Tumor microenvironment, Communications satellite

The third poster contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

Key Points: 
  • The third poster contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.
  • Location and time: Poster Hall: 9:00 a.m.– 7:00 p.m. PDT; Poster session Lunch 12:00 –1.30 p.m.; Poster reception 5:10 – 6:40 p.m.
  • Location and time: Poster Hall: 9:00 a.m.– 8.30 p.m. PDT; Poster session lunch 11:55 a.m. – 1:25 p.m.; Poster reception 7:00 – 8.30 p.m.
  • Title: Arginase-1 vaccine promotes T cell immunity against arginase 1+ cells, controls tumor growth via immune modulation of tumor microenvironment
    Location and time: Poster Hall: 9 a.m.– 7 p.m. PDT; Poster session lunch 12:00 – 1.30 p.m.; Poster reception 5:10 – 6:40 p.m.

Hi-Tech Pharmaceuticals Launches KRANK3D® Pre-Workout Supplement

Retrieved on: 
Tuesday, August 1, 2023
Taste, HCL, High, Marketing, Enzyme, Innovation, NOS, Nitro, Wheat, Armindo Cadilla, Research and development, Vasodilation, Athlete, Nitric oxide, NO, Performance, Head, Agmatine, High tech, Arginase, BEC, Ultimate, Gummy candy, Arginine, Fine chemical, Research

This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.

Key Points: 
  • This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.
  • We believe that it will quickly become the go-to pre-workout supplement for aspiring athletes and gym goers looking to take their training to the next level."
  • "KRANK3D® is an innovative, intense, wicked pre-workout energy supplement that will be the Cadillas of our preworkout stable, which includes: Mesomorph®, Jack3D®, Ultimate Orang®, and Wicked®.
  • Not only does this new state-of-the-art formula hit harder, it also tantalizes your taste buds like never before.

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Retrieved on: 
Thursday, March 2, 2023
Linda, Patient, MBA, License, DSM-IV codes, FDA, European Medicines Agency, Clinical trial, Marketing, OLE, Arginase, Homocystinuria, Safety, MD, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Therapy, LTE, EMA, Food, Investigational New Drug, Pharmaceutical industry, Management, Cryptocurrency, Cystinuria

AUSTIN, Texas, March 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.

Key Points: 
  • Research and development expenses totaled $14.3 million for the fourth quarter of 2022 and $16.8 million for the fourth quarter of 2021.
  • General and administrative expenses totaled $5.0 million for the fourth quarter of 2022 and $7.3 million for the fourth quarter of 2021.
  • Net loss totaled $18.8 million and $20.4 million for the fourth quarter of 2022 and 2021, respectively, which includes non-cash stock compensation expense of $1.4 million and $2.1 million for the fourth quarter of 2022 and 2021, respectively.
  • As of December 31, 2022, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $57.3 million.

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

Retrieved on: 
Monday, August 29, 2022
HCU, Enzyme, Protalix BioTherapeutics, Safety, Arginase, Lists of diseases, NASDAQ, Engineering, Cystathionine, Emory University School of Medicine, Arginine, Multimedia, Therapy, Society, Patient, CBS, Pharmaceutical industry, Tutoring, Homocystinuria, MD, Metabolism

AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 September 2.

Key Points: 
  • AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 September 2.
  • Aeglea is investigating AGLE-177 in an ongoing Phase 1/2 clinical trial for the treatment of Homocystinuria.
  • Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical trial and has received both Rare Pediatric Disease and Breakthrough Therapy Designations.
  • Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Retrieved on: 
Wednesday, August 24, 2022
Mortality, Osteoporosis, Enzyme, COVID-19, Security (finance), Survival, Research, Arginase, Lists of diseases, Intellectual disability, NASDAQ, Seizure, Engineering, MAA, Risk, SEC, Frank Lenti, Arginine, U.S. Securities and Exchange Commission, Multimedia, Spasticity, Homocysteine, Leadership, Plasma, Company, Therapy, FDA, Compte rendu, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Homocystinuria

AUSTIN, Texas, Aug. 24, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria.

Key Points: 
  • AUSTIN, Texas, Aug. 24, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria.
  • The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date.
  • "The restructuring announced today increases the operational focus and capital deployment towards success of the AGLE-177 program in Homocystinuria," said Russell J. Cox, chair of the board of directors of Aeglea.
  • Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Retrieved on: 
Tuesday, April 12, 2022
People, BLA, Intellectual disability, Orphan, Plasma, Therapy, MAA, Seizure, Risk, Forward-looking statement, Spasticity, Multimedia, Arginine, Mortality, European Medicines Agency, Homocystinuria, SEC, Achievement, Food, Securities and Exchange Commission (Philippines), Arginase, Private Securities Litigation Reform Act, OLE, Biologics license application, Review, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, Enzyme, Annual report, FDA, Engineering, Patient, Disease, Security (finance), Pharmaceutical industry, Dietary supplement

AUSTIN, Texas, April 12, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Aeglea requested FDA Priority Review at the time of the BLA submission.

Key Points: 
  • Aeglea requested FDA Priority Review at the time of the BLA submission.
  • The FDA has granted pegzilarginase multiple regulatory designations, including Rare Pediatric Disease, Breakthrough Therapy, Fast Track and Orphan Drug designations.
  • Aeglea is developing pegzilarginase for the treatment of people with Arginase 1 Deficiency (ARG1-D), a rare debilitating and progressive disease characterized by the accumulation of arginine.
  • In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency.

Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022

Retrieved on: 
Wednesday, April 6, 2022
Company, Therapy, Event, Multimedia, Homocystinuria, EDT, Conference, Arginase, Lists of diseases, Enzyme, Engineering, Patient, Pharmaceutical industry, Online shopping

A replay of Company webcasts is archived on the website for 30 days following presentations.

Key Points: 
  • A replay of Company webcasts is archived on the website for 30 days following presentations.
  • Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
  • In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency.
  • Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria.

Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting

Retrieved on: 
Tuesday, March 29, 2022
Company, Therapy, American Academy of Neurology, Society, Multimedia, Arginine, Homocystinuria, Arginase, Virtual, Annual general meeting, Lists of diseases, American Academy, Engineering, AAN, Enzyme, SIMD, Patient, Disease, Pharmaceutical industry

The Company will present additional data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D) at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in Orlando, FL.

Key Points: 
  • The Company will present additional data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D) at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in Orlando, FL.
  • Society for Inherited Metabolic Disorders Annual Meeting (April 10-13, 2022)
    Title: Pegzilarginase in Arginase 1 Deficiency: Results of the PEACE Pivotal Phase 3 Clinical Trial
    American Academy of Neurology Annual Meeting (Live: April 2-7, 2022; Virtual: April 24-26, 2022)
    About Aeglea BioTherapeuticsAeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
  • In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency.
  • Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria.

Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency

Retrieved on: 
Tuesday, January 25, 2022
Patient, Metabolism, Mount Sinai, Committee, KOL, Division, Congenital disorders of amino acid metabolism, Enzyme, Protalix BioTherapeutics, Program, Homocystinuria, Ann, Disease, Arginase, Icahn School of Medicine at Mount Sinai, Arginine, Birth, Company, Hospital, Lists of diseases, Inborn errors of metabolism, Therapy, Multimedia, Human Genome Sciences, Child, Engineering, Event, Feinberg School of Medicine, Pharmaceutical industry, Residential care, Pediatrics, Genetics

Tanja Brandt, parent/caregiver of a 10-year-old child with Arginase 1 Deficiency, Advisor and Steering Committee Member of the Arginase 1 Deficiency Foundation (ARG1D.org),will discuss the disease burden and will provide the patient and caregiver perspective related to the challenges of living with a devastating and progressive disease.

Key Points: 
  • Tanja Brandt, parent/caregiver of a 10-year-old child with Arginase 1 Deficiency, Advisor and Steering Committee Member of the Arginase 1 Deficiency Foundation (ARG1D.org),will discuss the disease burden and will provide the patient and caregiver perspective related to the challenges of living with a devastating and progressive disease.
  • To register for the webinar, please click here .To access the live and/or archived webcast, visit the Events & Presentations section of the Company's website.
  • Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
  • In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency.

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022

Retrieved on: 
Wednesday, January 5, 2022
Engineering, Event, Enzyme, Therapy, Company, Patient, Homocystinuria, Conference, EST, Lists of diseases, Multimedia, Arginase, Pharmaceutical industry, Online shopping

A replay of Company webcasts is archived on the website for 30 days following presentations.

Key Points: 
  • A replay of Company webcasts is archived on the website for 30 days following presentations.
  • Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
  • Aeglea has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria.
  • Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.